Cholangiocarcinoma News
Subscribe

Hot Topics in Cholangiocarcinoma From the 2024 Cholangiocarcinoma Foundation Annual Conference

CCF Highlights
Videos — May 15, 2024

Featuring:

Kelly Butler, BA
Medical Student, CCF Volunteer
Yale School of Medicine
New Haven, CT
Vaibhav Sahai, MBBS, MS
Associate Professor
Section Head GI Oncology
Division of Hematology and Oncology
University of Michigan
Ann Arbor, MI

On April 19, 2024, we presented an overview of cholangiocarcinoma (CCA)-themed abstracts at the 2024 Cholangiocarcinoma Foundation (CCF) Annual Conference. Additionally, we provided in-depth perspectives on the impact of the data on managing patients with CCA.

Related Items

Artificial Intelligence and Clinical Experience: Shaping the Future of CCA Care
CCF Highlights
June/July 2026, Vol 7, No 2
A look at how the synergy between artificial intelligence and clinical expertise is potentially shaping the outlook of cholangiocarcinoma care.
Read More
Cholangiocarcinoma Clinical Trials: Debunking Myths, Uncovering Facts, and Exploring Opportunities
CCF Highlights
June/July 2026, Vol 7, No 2
Uncover how clinical trials are transforming cholangiocarcinoma treatment, offering patients personalized therapies, expanded options, and new hope for the future.
Read More
The Changing Paradigm of Cellular Immunotherapy in Cholangiocarcinoma
CCF Highlights
June/July 2026, Vol 7, No 2
Explore how cellular immunotherapy, from tumor-infiltrating lymphocytes to circulating tumor-reactive T cells, is expanding the treatment landscape for cholangiocarcinoma.
Read More
Antibody-Drug Conjugates in Biliary Tract Cancers
CCF Highlights
June/July 2026, Vol 7, No 2
Antibody-drug conjugates show potential in cancer treatment and may signal new possibilities for biliary tract cancer patients in this significant exploration.
Read More
Advancing Hepatic Arterial Infusion Pump Chemotherapy for Intrahepatic Cholangiocarcinoma: Boosting Survival and Quality of Life
CCF Highlights
June/July 2026, Vol 7, No 2
Hepatic arterial infusion pump chemotherapy is transforming treatment for intrahepatic cholangiocarcinoma by improving survival rates and enhancing quality of life.
Read More
Exploring Protein Arginine Methyltransferases as Promising Therapeutic Targets in Cholangiocarcinoma
CCF Highlights
June/July 2026, Vol 7, No 2
Targeting protein arginine methyltransferases offers a promising new approach to combat cholangiocarcinoma by suppressing tumor growth and enhancing immune responses.
Read More
Advancing CAR T Cell Therapy for Cholangiocarcinoma
CCF Highlights
June/July 2026, Vol 7, No 2
Discover how emergent research on CAR T-cell therapy is paving the way for new possibilities in cholangiocarcinoma treatment.
Read More
Overcoming Therapeutic Resistance in Cholangiocarcinoma: Exploring Combination Strategies and Adaptive Lineage States
CCF Highlights
June/July 2026, Vol 7, No 2
Cutting-edge research on therapeutic resistance and innovative combination strategies is adding new possibilities to the fight against cholangiocarcinoma.
Read More
Biomarker Discovery and Early Detection in CCA
CCF Highlights
June 2025, Vol 6, No 2
Experts unveiled a roadmap for translating cutting-edge biomarkers into clinical practice, paving the way for improved early detection and personalized care in high-risk populations with cholangiocarcinoma (CCA).
Read More
Translational Science and Discovery in CCA
CCF Highlights
June 2025, Vol 6, No 2
Leading experts explored groundbreaking advancements in tumor microenvironments, biomarker validation, and innovative therapies, paving the way for transformative precision medicine in cholangiocarcinoma (CCA) care.
Read More

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Profession or Role
Primary Specialty or Disease State

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly CCA News print publication and CCA News weekly e‑newsletter.

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.